Taiyen Biotech Co., Ltd. (TPE:1737)

Taiyen Biotech Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	1,417	1,551	1,445	1,529	1,726	1,506
Short-Term Investments	-	-	4.24	-	1.06	1.93
Trading Asset Securities	356.35	346.32	390.61	353.18	353.54	381.04
Cash & Short-Term Investments	1,773	1,898	1,840	1,882	2,080	1,889
Cash Growth	-7.02%	3.16%	-2.27%	-9.52%	10.15%	-4.10%
Accounts Receivable	531.22	498.3	663.23	650.28	757.6	540.86
Other Receivables	6.18	6.23	23.43	32.78	7.19	33.96
Receivables	537.4	504.53	686.66	683.06	764.79	574.82
Inventory	361.07	427.32	394.74	407.37	395.02	315.56
Other Current Assets	216.47	97.95	105.27	121.26	154.52	121.44
Total Current Assets	2,888	2,927	3,026	3,094	3,395	2,900
Property, Plant & Equipment	4,007	4,023	3,905	3,713	3,564	3,431
Long-Term Investments	-	-	33.96	-	-	-
Other Intangible Assets	10.91	11.71	6.41	5.34	8.53	8.02
Long-Term Deferred Tax Assets	63.65	63.65	81.9	72.12	87.22	64.43
Other Long-Term Assets	1,350	1,355	1,266	1,327	1,413	1,393
Total Assets	8,320	8,381	8,320	8,212	8,468	7,798
Accounts Payable	417.53	419.51	384.5	399.06	485.3	273.15
Short-Term Debt	95	98	100	20	287.53	30
Current Portion of Long-Term Debt	9.17	66.95	15.31	8.65	4.29	4.29
Current Portion of Leases	7.97	8.76	7.26	9.27	10.76	15.16
Current Income Taxes Payable	71.15	43.36	66.29	42.17	79.75	47.22
Current Unearned Revenue	141.31	109.76	98.03	102.23	79.02	33.18
Other Current Liabilities	283.61	418.81	429.62	344.67	358.74	291.88
Total Current Liabilities	1,026	1,165	1,101	926.05	1,305	694.88
Long-Term Debt	3.89	5.56	72.5	68.93	53.08	57.37
Long-Term Leases	24.67	25.93	25.09	28.59	36.33	100.53
Long-Term Unearned Revenue	294.6	297.72	307.19	320.05	332.92	345.78
Long-Term Deferred Tax Liabilities	39.44	39.44	34.38	34.23	34.08	33.93
Other Long-Term Liabilities	136.78	142.08	136.68	109.52	83.67	76.49
Total Liabilities	1,563	1,714	1,771	1,550	1,954	1,433
Common Stock	2,000	2,000	2,000	2,000	2,000	2,000
Additional Paid-In Capital	2,502	2,502	2,502	2,502	2,502	2,502
Retained Earnings	2,262	2,165	1,993	2,022	1,862	1,731
Comprehensive Income & Other	-2.1	-2.63	-3.38	-2.99	-2.16	-2.99
Total Common Equity	6,762	6,664	6,491	6,521	6,361	6,229
Minority Interest	-4.92	3.53	57.6	140.69	152.2	134.75
Shareholders' Equity	6,757	6,668	6,549	6,662	6,513	6,364
Total Liabilities & Equity	8,320	8,381	8,320	8,212	8,468	7,798
Total Debt	140.7	205.2	220.17	135.44	391.98	207.35
Net Cash (Debt)	1,633	1,692	1,619	1,747	1,688	1,681
Net Cash Growth	-1.63%	4.51%	-7.29%	3.46%	0.42%	-3.60%
Net Cash Per Share	8.14	8.44	8.08	8.71	8.42	8.38
Filing Date Shares Outstanding	200	200	200	200	200	200
Total Common Shares Outstanding	200	200	200	200	200	200
Working Capital	1,863	1,762	1,925	2,168	2,089	2,206
Book Value Per Share	33.81	33.32	32.46	32.61	31.81	31.15
Tangible Book Value	6,751	6,652	6,485	6,516	6,353	6,221
Tangible Book Value Per Share	33.76	33.26	32.42	32.58	31.76	31.11
Land	1,816	1,816	1,816	1,816	1,736	1,684
Buildings	1,579	1,568	1,423	1,354	1,322	1,300
Machinery	3,605	3,507	3,004	2,837	2,844	2,880
Construction In Progress	112.29	186.56	632.49	440.46	323.04	182.56

Source: S&P Global Market Intelligence. Standard template. Financial Sources.